The alliance with AstraZeneca was established in 2016 to connect academic and industry scientists in cancer research, and promote collaboration with the CRUK Cambridge Centre and all who fall under its umbrella thereby accelerating both AstraZeneca’s core purpose to “push the boundaries of science to deliver life changing medicines” and CRUK CC vision “To be a world leader in the development of ways to detect, monitor and cure cancer”.
The MFICM collaborates with AstraZeneca currently through four prospective clinical trials: PARTNER/PARTNERING, ATRiUM, WIRE and DIRECT, which are part of the MFICM portfolio.
